Wire · opportunities
From $8.6 bln to $110 bln: the decade‑long surge of CAR‑T therapies
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 September 2026 · Fusion42 review
The global CAR-T cell therapy market is projected to grow from $8.6 billion in 2025 to around $110 billion by 2034, driven by rising patient numbers and expanding indications despite high treatment costs. Key pharmaceutical players are accelerating production innovation and expanding clinical trials to include solid tumours and autoimmune diseases, while regulatory environments differ with the US easing access and Europe imposing cost-effectiveness restrictions.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face rapidly expanding opportunity as CAR-T therapies move beyond blood cancers into solid tumours and autoimmune diseases. Adjust your development plans now to target these new indications before competitors seize early market share.
◆ Coverage
1 source · 1 Sep 2026
◆ Related on Wire
◆ Topics